Evidence map›Paper›PMID 42365136›Full record

ArticleBritish journal of cancer2026

Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.

Fengqi Chen, Ying Chen, Wenke Sun, Hanke Ma, Yihao Liang, Yutong Li, Jing Li, Xiaobin Cao, Songyun Ouyang, Liping Dai

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Fengqi ChenHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Ying ChenHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Wenke SunHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Hanke MaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Yihao LiangHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Yutong LiHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Jing LiHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Xiaobin CaoHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Songyun OuyangDepartment of Respiratory and Sleep Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liping DaiHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China. lpdai@zzu.edu.cn.ORCID http://orcid.org/0000-0002-5531-1776

Funding

National Natural Science Foundation of China (National Science Foundation of China) 8167291
6 · The paper itself

Abstract

backgroundTumour associated autoantibody (TAAb) generated against cell membrane receptor proteins in lung cancer have attracted attention. Understanding the role of these autoantibodies in tumours may open up new therapeutic modalities.

methodsPlasma samples from 1170 participants were used to detect TAAbs level by enzyme-linked immunosorbent assay (ELISA) for evaluating the diagnostic value of candidate TAAbs. 353 non-small cell lung cancer (NSCLC) cases were used to assess the prognostic value of anti-platelet-derived growth factor receptor alpha (PDGFRα) autoantibody. The impact and mechanisms of anti-PDGFRα autoantibody were explored through antibody absorption, CCK-8, transwell, wound healing, and angiogenesis assays in NCI-H1703 cell.

resultsAnti - PDGFRα autoantibody was overexpressed in NSCLC and had an AUC of 0.747 (95% CI: 0.701-0.794) for early diagnosis compared to normal individuals. Cox regression analysis showed that it could be served as an independent predictor of poor prognosis in NSCLC with a HR of 1.510 (95% CI: 1.094-2.098). In vitro results suggested a role of anti-PDGFRα in promoting proliferation, migration, and angiogenesis via PI3K/AKT/NF-κB pathway.

conclusionsAnti-PDGFRα autoantibody is a novel biomarker for early diagnosis and poor prognosis of NSCLC. The mechanisms exploration may provide the theoretical basis for the precision treatment of NSCLC targeting anti-PDGFRα autoantibody.

Indexed as

AutoantibodiesBiomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsReceptor, Platelet-Derived Growth Factor alphaAgedCell Line, TumorDisease ProgressionFemaleHumansMaleMiddle AgedNF-kappa BPhosphatidylinositol 3-KinasesPrognosisProto-Oncogene Proteins c-aktAutoantibodiesBiomarkers, TumorNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID42365136
PMCPMC13578718

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.